Radiosynthesis and quality assurance of 5-[124I]Iodo-2'-deoxyuridine for functional PET imaging of cell proliferation

Nuclear Medicine and Biology

Volumn 25, Issue 4, 1998, Pages 359-365

  Guenther, Ilonka ^b   Wyer, Leo ^a   Knust, E Joachim ^c   Finn, Ronald D ^d   Koziorowski, Jacek ^a   Weinreich, Regin ^a  

^a CH 5232   (Switzerland)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

5 124I Iodo 2' deoxyuridine; Cell proliferation; Positron emission tomography; Quality assurance; Radiolabelling; Routine production

Indexed keywords

IDOXURIDINE; IODATE; IODIDE; IODINE 124; IODINE 125; IODINE 131;

ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG FORMULATION; DRUG HALF LIFE; DRUG PURIFICATION; DRUG STABILITY; DRUG SYNTHESIS; GLIOMA; HUMAN; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; QUALITY CONTROL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; THIN LAYER CHROMATOGRAPHY;

CELL DIVISION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; GLIOMA; HUMANS; IDOXURIDINE; IODINE RADIOISOTOPES; QUALITY ASSURANCE, HEALTH CARE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031971928     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(97)00220-5     Document Type: Article

References (29)

1. 125IUdR) by resistant cancer. Br. J. Radiol. 64:1991;37-44.
2. 123/125/127I]Iodo-2′-deoxyuridine . Appl. Radiat. Isot. 39:1988;335-341.
3. 124I]Iododeoxyuridine imaging tumor proliferation. J. Nucl. Med. 37:(suppl.):1996;59.
4. Burgess J. S., Partington E. J. Radiation decomposition effects in aqueous solutions of carrier-free sodium iodide I-131. UKAEA Report RCC/R. 98:1960.
5. 11C]thymidine. Proc. Natl. Acad. Sci. USA. 69:1972;988-992.
6. 3H-thymidine in mouse duodenum and mammary tumor. J. Natl. Cancer Inst. 44:1970;827-840.
7. 123I reactions from 7 to 24 MeV . Nucl. Instr. Meth. Phys. Res. B79:1993;909-910.
8. 124I reaction and an improved recovery method for Te-124. J. Label. Compd. Radiopharm. 35:1994;257-259.
9. Foulon C. F., Adelstein S. J., Kassis A. I. Kit formulation for the preparation of radiolabeled iododeoxyuridine by demetallation. J. Nucl. Med. 37:(suppl.):1996;1S-3S.
10. Fraker P. J., Speck J. C. Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem. Biophys. Res. Commun. 80:1978;849-857.
11. 124I. J. Clin. Endocrinol. Metab. 63:1986;918-927.
12. 18F]fluoro-L-dopa in rhesus monkey . Nucl. Med. Biol. 22:1995;921-927.
13. 131 in the mouse and rat. Cancer Res. 21:1961;345-352.
14. 125IUdR in mammalian cells Implications of localized energy deposition by Auger processes . Radiat. Res. 109:1987;78-89.
15. Klecker R. W., Jenkins J. F., Kinsella T. J., Fine R. L., Strong J. M., Collins J. M. Clinical pharmacology of 5-iodo-2′-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation. Clin. Pharmacol. Ther. 38:1985;45-51.
16. 124I in different production reactions. In: Proceedings of the Seventh International Workshop on Targetry and Target Chemistry. (Edited by Zeisler S. and Helus F.) Deutsches Krebsforschungszentrum, German Cancer Research Centre, Heidelberg, Germany (in press).
17. 211At labeled 5-halo-2′-deoxyuridine. J. Radioanal. Nucl. Chem. 219:1997;127-128.
18. Kriss J. P., Révész L. Quantitative studies of incorporation of exogenous thymidine and 5-bromodeoxyuridine into deoxyribonucleic acid of mammalian cells in vitro. Cancer Res. 21:1961;1141-1147.
19. Lambrecht R. M., Sajjad M., Qureshi M. A., Al-Yanbawi S. J. Production of iodine-124. J. Radioanal. Nucl. Chem. Lett. 127:1988;143-150.
20. 125I]Iodo-2′-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J. Nucl. Med. 37:(suppl.):1996;25S-29S.
21. Molnar P., Groothuis D., Blasberg R., Zaharko D., Owens E., Fenstermacher J. Regional thymidine transport and incorporation in experimental brain and subcutaneous tumors. J. Neurochem. 43:1984;421-432.
22. Pentlow K. S., Graham M. C., Lambrecht R. M., Daghighian F., Bacharach S. L., Bendriem B., Finn R. D., Jordan K., Kalaigian H., Karp J. S., Robeson W. R., Larson S. M. Quantitative imaging of iodine-124 with PET. J. Nucl. Med. 37:1996;1557-1562.
23. Prusoff W. H., Jaffe J. J., Günther H. Studies in the mouse of the pharmacology of 5-iododeoxyuridine, an analogue of thymidine. Biochem. Pharmacol. 3:1960;110-121.
24. Shields A. F., Lim K., Grierson J., Link J., Krohn K. A. Utilization of labeled thymidine in DNA synthesis Studies for PET . J. Nucl. Med. 31:1990;337-342.
25. Tjuvajev J., Muraki A., Ginos J., Berk J., Koutcher J., Ballon D., Beattie B., Finn R., Blasberg R. Iododeoxyuridine uptake and retention as a measure of tumor growth. J. Nucl. Med. 34:1993;1152-1162.
26. Tjuvajev J. G., Macapinlac H. A., Daghighian F., Scott A. M., Ginos J. Z., Finn R. D., Kothari P., Desai R., Zhang J., Beattie B., Graham M., Larson S. M., Blasberg R. G. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J. Nucl. Med. 35:1994;1407-1417.
27. 18F-Fluoro-2′-deoxyuridine as a tracer of nucleic acid metabolism in brain tumors. J. Neurosurg. 72:1990;110-113.
28. 124I. J. Radioanal. Nucl. Chem., Lett. 213:1996;253-261.
29. Westera G., Reist H. W., Buchegger F., Heusser C. H., Hardman B., Pfeiffer A., Sharma H. L., Von Schulthess G. K., Mach J. P. Radioimmuno positron emission tomography with monoclonal antibodies A new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy . Nucl. Med. Commun. 12:1991;429-437.